Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) is one of three emerging companies that will present at Proactive’s virtual investor conference on Tuesday, February 16.
Hosted by Proactive's Christine Corrado, the event kicks off on Tuesday at 1 PM ET.
SIGN-UP: Proactive One2One February 16
This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
The company specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Most recently, Algernon Pharmaceuticals signed a deal with lab services firm Charles River Laboratories for pre-clinical research studies on the psychedelic compound DMT to treat stroke.
The company said it plans to be the first research entity globally to pursue DMT for stroke in humans and is targeting to begin a clinical trial as soon as possible this year.
Algernon joins Greenbank Capital and ProPhase Labs Inc on the event roster.